Regenerative meta-eye injection Eylea (aflibercept) yielded positive results in phase 3 trial PANORAMA

recently, Regeneration announced that thecompany(which has beenby theFDA (approved vascular endothelial growth factor (VEGF) inhibitor eye injection Eylea (aflibercept) and that thedrug(in the phase 3trial(in the positive results)PANORAMA is the first phase 3 trial for patients with non-proliferative retinopathy (NPDR), and week 52 data released show that Eylea reached the main and critical secondary endpoints of the trial, effectively reducing the likelihood of complications (VTCs) and diabetic macular edema (DME) that may affect visionEylea
Eylea is an eye injection that has been approved by the FDA for VEGF inhibitors, designed to inhibit the growth of new blood vessels and reduce vascular permeability by blocking the effects of two growth factors involved in vascular production, VEGF-A and placental growth factor (PLGF)so far, Elyea has received research support, including seven key Phase 3 clinical trialsPANORAMA, a two-year continuous double-blind randomized controlled trial of moderate to severe NPDR patients without DME, included 402 patients, including two Eylea injection groups and an observational comfort control group, with the injection group divided into 8 weeks or 16 weeksThe main endpoints of thetrial were designed to assess the proportion of patients with a two-degree or above improvement in the patient severity scale (DRSS) score for diabetic retinopathykey secondary endpoints include assessing whether Eylea can reduce the incidence of VTCs and DME, as well as other anatomical effects and effects and safety on vision improvement the latest results show that by the time the trial was conducted, both teams had reached the main and critical secondary ends of the trial The DRSS scores of 80% and 65% of patients in the two Eylea trial groups improved by two or more in week 52, compared with 15% in the control group (p 0.0001) In addition, Eylea was able to significantly reduce the incidence of VTCs by 82-85% compared to the control group, reducing the incidence of central diabetic macular edema (CI-DME) by 68-74%